CSTONE Aktie

>CSTONE Aktienkurs

1.01 EUR +0.0% (TradegateBSX)

Ask: 1.01 EUR / 1892 Stück

Bid: 0.975 EUR / 1971 Stück

Tagesumsatz: 7532 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CSTONE Aktie über LYNX handeln

Intraday

1 Jahr

>CSTONE Performance

1 Woche: +7,4%

1 Monat: +51,9%

3 Monate: +71,9%

6 Monate: +16,1%

1 Jahr: +188,6%

laufendes Jahr: +68,3%

>CSTONE Aktie

Name:

CSTONE PHARMAC. DL-,0001

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG2588M1006 / A2PEFW

Symbol/ Ticker:

PH4 (Frankfurt)

Kürzel:

FRA:PH4, ETR:PH4, PH4:GR

Index:

Webseite:

http://www.cstonepharma.c..

Profil:

CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative oncology therapies. It primarily focuses on developing groundbreaking treatments for cancer, addressing a range of unme..
>Volltext..

Marktkapitalisierung:

1471.03 Mio. EUR

Unternehmenswert:

1401.6 Mio. EUR

Umsatz:

32.73 Mio. EUR

EBITDA:

-46.25 Mio. EUR

Nettogewinn:

-52.62 Mio. EUR

Gewinn je Aktie:

-0.04 EUR

Schulden:

43.2 Mio. EUR

Liquide Mittel:

93.42 Mio. EUR

Operativer Cashflow:

Bargeldquote:

1.8

Umsatzwachstum:

-41.38%

Gewinnwachstum:

-320.42%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CSTONE

Letzte Datenerhebung:

04.04.26

>CSTONE Kennzahlen

Aktien/ Unternehmen:

Aktien: 1472.41 Mio. St.

Frei handelbar: 71.71%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 93

Umsatz/Mitarb.: 0.35 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 40.95%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -0.08

EV/EBITDA: -

Rentabilität:

Bruttomarge: 11.22%

Gewinnmarge: -160.77%

Operative Marge: -157.52%

Managementeffizenz:

Gesamtkaprendite: -31.57%

Eigenkaprendite: -88.04%

>CSTONE Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>CSTONE Chart & Kurs - Tradegate

>CSTONE News

26.03.26 - 20:15	Results: CStone Pharmaceuticals Annual Loss Widens to RMB437 Million (AAStocks)
	CStone Pharmaceuticals - B (02616.HK) announced its 2025 annual results, reporting revenue of RMB270 million, representing a year-on-year decrease of 33.8%. The loss expanded from RMB91.21 million in the previous year to RMB437 million, with a loss per share of RMB0.31. No final dividend was declared. (de/d)~AASTOCKS Financial N......

26.03.26 - 14:37	CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0 (PR Newswire)
	Rapid Advancement Across Core R&D Pipeline The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has been approved in the US. CS2009 demonstrates an......

26.03.26 - 13:55	CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) (PR Newswire)
	Key Highlights: Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with......

23.02.26 - 01:12	CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC (PR Newswire)
	Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the......

16.02.26 - 01:12	CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial (PR Newswire)
	CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development......

07.11.25 - 01:12	ACAAI 2025 \| CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut (PR Newswire)
	SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the......

20.10.25 - 02:12	ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) (PR Newswire)
	SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first......

09.07.25 - 03:45	CSTONE PHARMA-B Places 100M Shrs at ~9% Discount to Raise HKD472M (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 02:03	CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR (PR Newswire)
	SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007......

06.05.25 - 02:01	CStone Presents the Latest Preclinical Findings of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) at 2025 AACR (PR Newswire)
	SUZHOU, China, May 5, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that a poster presentation of preclinical data of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a......

27.03.25 - 12:57	CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress (PR Newswire)
	Financial Performance: Strong Year-over-Year Improvement - Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income. - Net Loss Reduction: 71.5% year-over-year improvement. Key Product Advancements - Sugemalimab (Anti-PD-L1 mAb) - Regulatory......

26.03.25 - 01:18	CStone to Showcase Five Latest Research Achievements at AACR 2025 (PR Newswire)
	SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the......

24.03.25 - 01:15	CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer (PR Newswire)
	SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for......

06.03.25 - 01:12	CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL (PR Newswire)
	Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor......

04.03.25 - 01:12	CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody (PR Newswire)
	SUZHOU, China, March 3, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram